StemCell Therapy

Winter can be hard for many people, but for cancer patients, slippery streets, and cold weather are more than a hazard, they can also be a health risk. Learn how cold weather affects cancer patients and how they can stay safe during the winter.

HypothermiaHypothermia is a condition where the human body begins to lose heat faster than it can produce it, causing the body temperature to become dangerously low. Side effects of cancer treatment, such as fatigue, dehydration, and anemia, can make patients more susceptible to hypothermia.

FrostbiteSome treatments can cause peripheral neuropathy, which carries numbness in the extremities as a potential side effect. Patients who have peripheral neuropathy are more likely to get frostbite since they cant feel how cold their fingers and hands are in cold weather.

FallsPatients can have a higher risk of fracture if they are receiving treatments that affect bone density. Cancer patients need to be especially careful if they have thrombocytopenia, a condition associated with blood cancers that cause low platelet counts. Since platelets help blood clot, a low count can mean that bruising or serious bleeding can happen when injured.

Patients who have numbness in their feet (neuropathy) are also more prone to falls.

FluCancer therapy may weaken patients immune systems. It is necessary that they get their flu shot since they dont have enough white blood cells to fight infections. This is why cancer patients have a higher chance of having complications from the flu than a healthy person.

Tips to Stay SafeFollow these tips to protect your health or a loved one in winter and stay safe:

If youd rather avoid winter and the risks it carries for cancer patients, you can always consider health tourism. Its the practice of traveling to a popular tourist destination with the purpose of receiving therapeutic treatment. For example, Florida has mild, pleasant winters, which make it an ideal location for health tourism!

Winter wont last forever, even if you sometimes feel that way, so celebrate each sunny day!

More than a thousand men and women diagnosed with cancer each year turn to our trusted team of cancer specialists at Tampa Bay Radiation Oncology. We encourage you to call us, ask us a question, or consult with us to get a second opinion so you, too, can experience the difference.

Featured image: Winter. Photo courtesy: 2020 Pixabay/Ina Hoekstra (Heerenveen, The Netherlands)

Read more from the original source:
How Cold Weather Affects Cancer Patients - OncoZine

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Diabetic Peripheral Neuropathy Treatment Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Diabetic Peripheral Neuropathy Treatment Market Overview

The Diabetic Peripheral Neuropathy Treatment Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Diabetic Peripheral Neuropathy Treatment market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Diabetic Peripheral Neuropathy Treatment Market: Competitive Landscape

The Diabetic Peripheral Neuropathy Treatment Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Diabetic Peripheral Neuropathy Treatment Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Diabetic Peripheral Neuropathy Treatment Market Segment by Type:

Diabetic Peripheral Neuropathy Treatment Market Segment by Application:

Diabetic Peripheral Neuropathy Treatment Market Regional overview:

In the report, experts analyze and forecast the Diabetic Peripheral Neuropathy Treatment market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Diabetic Peripheral Neuropathy Treatment Market Report:

Outlook analysis of the Diabetic Peripheral Neuropathy Treatment market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Diabetic Peripheral Neuropathy Treatment market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Go here to see the original:
Diabetic Peripheral Neuropathy Treatment Market Size, Analysis, Growth, Trends, Outlook And Forecast By 2027 - The Haitian-Caribbean News Network

As we attempt to protect our elderly population in this pandemic, this is what I see when I look through the window,

I look into the window as she awakens to the sound of business outside the door. I can tell that she is not sure who is outside her door. For that matter not sure of the day or time. Is it Wednesday, or Saturday. They all seem the same, day after day unchanging. Someone enters her room with very little conversation. No small talk, places her breakfast box on the tiny table by her chair. I see her say hello and smile at the woman, she just turns to leave. She slowly opens the Styrofoam box to find watery eggs and sausage and a cup of coffee. Her neuropathy wont allow her to open the sugar that she would love to have added to her coffee, but the woman is already gone. She tries to open it but finally puts it down and she just drinks it black. I watch her struggle to eat a few bites of the eggs, dropping them on her shirt. I think she finally figured it is morning. I see she has her TV on, but I know she cant hear much of the show as she is hearing impaired. I notice it has the closed caption on again. I guess she was trying to change the channel. She just cant use that remote and I cant get in to change it myself. She just sits listlessly staring ahead. Loneliness. Is what I see!

I knock on her window to get her attention. She finally looks up. She smiles, it makes me sad to see her happy just to see me through the window, but it is all I can do. Her hair is so disheveled. She would have never looked like this. She always had a standing appointment at the beauty shop weekly for a wash and style. But I guess it doesnt matter, she doesnt ever see her hair. She goes nowhere, only sitting in her room. Alone. I wave at her smiling, while fighting back tears. I hold up my phone to motion that I am going to call her room. I can hear it ringing. I watch her slowly reach for the phone. It continues to ring. Again her neuropathy slows her so much my call is forwarded to voice mail. I call back but now get an instant message. She has not ended the previous call. I finally call the facility and ask someone to please go to her room and help her answer the phone. She smiles as she hears my voice. Why cant these phones be like they used to be? Why cant I just answer it when someone calls me so I can talk to them? Can you please find me a phone like I used to have? Why do I have to push buttons? I cant remember which buttons to push. I just cant use this phone.

Another person with face covered, enters the room, hands her some pills and a sip of water. They are quickly gone. Alone again. She asks if I can just come in for a minute, she has something she wants to tell me. I try to explain that I cant come in at all. I would love to, but I am not allowed. I can only watch from outside the window. She tries to tell me something about last night, but her story is hard to follow. She was never like this, always so lucid with organized thought. This is all changing as I watch from outside the window. She again asks if I can get an appointment to see her. I feel like she thinks she is forgotten; the loneliness is overwhelming. She cannot understand why I dont visit.

I see her plant in the window sill, it needs watering. I tell her the plant needs a drink. But I know she cant water it and the people here are too busy she says. We talk about her breakfast, and I tell her I brought her a few goodies they will deliver to her room. She smiles. I finally tell her that Im leaving as it is cold outside. The smile fades and she says again can you come in for just a minute?

This is what I see from the window! This is one visit at her long term care facility. These visits are increasingly painful to watch and be a part of. The longer she is kept from her family, the worse she gets cognitively and physically. I see the sadness. I see the decline in her health through this window. I know there are others seeing the same as they look through their loved ones windows. The only thing these precious people have done wrong is get old. Now they are forced to live out their last days all alone. I understand we are trying to protect the frail and elderly, but is that really what we are doing?

Teresa Peers

* * *

Amen to Teresa Peers! You are not alone in this fight. I know all the facilities are doing their best to keep people safe, but at what cost?

I think many would choose to take a chance on the virus versus the isolation.

From one caregiver to another, I hear you.

Jeannie Hixon

See the article here:
Our Elderly In Isolation - And Response - The Chattanoogan

A once-per-week selinexor (Xpovio), bortezomib (Velcade), plus dexamethasone treatment strategy appeared effective and convenient as treatment of patients with multiple myeloma who received at least 1 to 3 prior lines of therapy, according to findings from the phase 3, randomized, open-label BOSTON trial.

The study was conducted across 123 sites in 21 countries, and patients were randomized 1:1 to 1 of 2 arms; patients received selinexor 100 mg once per week, bortezomib 1.3 mg/m2 once per week, and dexamethasone 20 mg twice per week, or in the second arm, patients were treated with bortezomib 1.3 mg/m2twice per week for the first 24 weeks and once per week thereafter and dexamethasone 20 mg 4 times per week for the first 24 weeks and twice per week thereafter.

The primary end point of the study is progression-free survival (PFS), and secondary end points included objective response rate (ORR), overall survival (OS), and duration of response (DOR), as well as PFS and ORR in patients who crossed over from the control arm, PFS on subsequent line of therapy, time to next anti-multiple myeloma treatment, time to response, incidence of grade 2 or higher peripheral neuropathy events, and patient-reported peripheral neuropathy. Safety and tolerability were also reviewed as additional secondary end points.

The median age of patients in the experimental arm was 66 years (range, 59-72) compared with 67 years (range, 61-74) in the control arm, and the majority of patients were male in both arms (59% and 56%, respectively). Among patients randomized to the triplet arm (n = 195), 54% had an ECOG performance status of 1, 35% 0, and 10% 2, compared with 55%, 37%, and 8% in the control arm, which included 207 patients total. Most patients (51%) had received 1 prior line of therapy in the experimental arm versus 48% in the control, while 33% and 31% had 2 prior lines, and 16% and 21% had 3 prior lines, respectively.

Overall, the PFS was significantly longer with the triplet regimen compared with bortezomib and dexamethasone alone. The median PFS was 13.93 months (95% CI, 11.73-not evaluable [NE]) in the experimental arm versus 9.46 months (95% CI, 8.11-10.78) in the control arm (HR, 0.70; 95% CI, 0.53-0.93; P=.0075).

The ORR was significantly higher with the once-per-week regimen at 76.4% (95% CI, 69.8-82.2) compared with 62.3% (95% CI, 55.3-68.9) in the control arm (OR, 1.96; 95% CI, 1.3-3.1; P =.0012). In the triplet arm, the proportion of patients with a very good partial response or was 44.6% (95% CI, 37.5-51.9) compared with 32.4% (95% CI, 26.0-39.2) in the bortezomib plus dexamethasone arm (OR, 1.66; 95% CI, 1.1-2.5; P =.0082). The proportion of patients with stable disease or progressive disease as their best response was also lower in the triplet arm at 13.3% (95% CI, 8.9-18.9) compared with 24.2% in the control arm (95% CI, 18.5-30.6).

The median time to first response of a partial response or better was 1.1 months (interquartile range [IQR], 0.8-1.6) in the triplet arm versus 1.4 months (IQR, 0.8-1.6) in the control arm. The median duration of response was longer with the once-per-week regimen at 20.3 months (95% CI, 12.5-NE) compared with 12.9 months (95% CI, 9.3-15.8) in the control (HR, 0.81; 95% CI, 0.56-1.17; P =.1364). The median time to next anti-myeloma therapy was longer in the triplet arm as well at 10.8 months (95% CI, 9.8-13.4) versus 0.66 (95% CI, 0.50-0.86) in the control (P =.0012).

Overall, 47 patients (24%) died in the experimental arm compared with 62 (30%) in the control arm. The median OS was not reached after a median follow-up of 17.3 months in the triplet arm (IQR, 12.9-20.3) versus 25 months (95% CI, 23.5-NE) after 17.5 months follow-up in the experimental arm (HR, 0.84; 95% CI, 0.57-1.23; P =.1852).

In the safety analysis, 195 patients from the triplet arm and 204 from the doublet arm were included. The most common treatment-emergent adverse events (AEs) of grade 3/4 included thrombocytopenia (39% vs 17%), anemia (16% vs 10%, pneumonia (12% vs 10%), and fatigue (13% vs 1%), and these all occurred in higher incidences in the triplet arm compared with the control, respectively.

Treatment was discontinued in 41 (21%) of patients in the experimental arm versus 32 (16%) in the control arm due to treatment-emergent AEs. The most common reasons for treatment discontinuation included peripheral neuropathy (5%), fatigue (4%), nausea (3%), vomiting (2%), decreased appetite (2%), and thrombocytopenia (2%) in the triplet arm, and the most common reason in the control arm was peripheral neuropathy (7%).

The median time to treatment discontinuation was 194 days (IQR, 100-332) in the experimental arm versus 184 (IQR, 106-276) in the control arm, and among all patients who had discontinued, 19 (46%) in the once-per-week arm and 16 (50%) in the bortezomib and dexamethasone arm were over the age of 70 years.

Dose modifications were common in the triplet arm, occurring in 173 (89%) of patients compared with 156 (76%). Most of the side effects that were associated with selinexor were reversible and were mitigated with standard supportive care.

Serious AEs occurred in 101 (52%) of patients in the once-per-week arm versus 77 (38%) in the control arm, and the most frequent serious AE was pneumonia, occurring in 12% of each arm.

Overall, this study demonstrated a significant increase in PFS for patients previously treated with multiple myeloma when treated with the triplet versus the control arm of bortezomib with dexamethasone. The benefit was observed across subgroups, and the improved efficacy was particularly notable in that it was achieved during the first 24 weeks of therapy, according to the study authors.

Reference

Grosicki S, Simonova M, Spicka I, et al.Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.Lancet. 2020;396(10262):P1563-1573. doi: 10.1016/S0140-6736(20)32292-3

More here:
Once-Per-Week Selinexor Triplet Appears Effective in Patients With Multiple Myeloma - Targeted Oncology

Ischemic optic neuropathy is caused due to a small vessel infraction of the optic nerve and is a major cause of blindness or impaired vision among the inflicted. There are two types of ischemic optic neuropathies viz. anterior ischemic optic neuropathy and posterior or non-anterior ischemic optic neuropathy. Anterior ischemic optic neuropathy is caused by the inflammation of arteries supplying blood to the optic nerve whereas posterior or non-anterior ischemic optic neuropathy is caused due to reasons other than inflammation of the arteries. Anterior ischemic optic neuropathy is more prevalent as compared to posterior ischemic optic neuropathy. In anterior ischemic optic neuropathy, immediate treatment is required to prevent vision loss in the fellow eye as approximately 50 percent of cases have chances of blindness in another eye within a span of 5 to 10 days without treatment. The symptoms of ischemic optic neuropathy include unilateral, acute and painless visual loss for hours to days. Hypertension, diabetes, and hypercholesterolemia are some of the well-known risk factors associated with ischemic optic neuropathy disease. Other factors include generalized hypoperfusion, sleep apnea, nocturnal hypotension, vasospasm, severe anemia and failure of autoregulation.

To remain ahead of your competitors, request for a sample [emailprotected]https://www.persistencemarketresearch.com/samples/23077

Technological advancements in ischemic optic neuropathy treatment and availability of alternative drugs are anticipated boost the demand for ischemic optic neuropathy treatments over the forecast period.

The global ischemic optic neuropathy treatment market can be segmented on the basis of disease type, treatment type and end user.

On the basis of disease type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of treatment type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of end user, the global ischemic optic neuropathy treatment market can be segmented into:

To receive Methodology request here@https://www.persistencemarketresearch.com/methodology/23077

The global ischemic optic neuropathy treatment market is expected to register a significant CAGR over the forecast period. The increasing adoption of recently approved intravitreal implants in the treatment of ophthalmology diseases is anticipated to propel the growth of the ischemic optic neuropathy treatment market over the forecast period. Leading pharmaceutical and drug manufacturing companies from developed countries are substantially investing in R&D, infrastructure and new technologies in ophthalmology therapeutics to capture a market share in the growing burden of eye diseases, which also boosts the growth of the global ischemic optic neuropathy treatment market. With growing awareness towards eye-related complications that lead to blindness, geriatric population and diabetic patients in developed countries, such as the U.S., Russia, and Poland, Germany and Japan are seen to have a proactive approach for treatment related to complications rather than reactive treatment, which also bolsters the growth of the market of ischemic optic neuropathy treatment.

Corticosteroid is the first choice of therapy for patients with ischemic optic neuropathy in prominent countries, such as the U.S., Germany, France, and Russia; however, a majority of patients have developed resistance to anti-VEGF, which leads to the adoption of alternative therapy in patients with ischemic optic neuropathy. This is anticipated to drive the growth of the global ischemic optic neuropathy treatment market in the long run.

To receive extensive list of important regions, Request TOC here @https://www.persistencemarketresearch.com/toc/23077

However, medications such as intravitreal injections of anti-VEGF drugs and corticosteroids lead to an instant increase in intraocular pressure, which may lead to severe adverse effects such as conjunctival haemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased and vitreous detachment. This may restrain the growth of the global ischemic optic neuropathy treatment market.

On the basis of regional presence, the global ischemic optic neuropathy treatment market can segmented into five key regions, namely North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa.

North America is a dominant region in the market and contributes a leading share to the global ischemic optic neuropathy treatment market in terms of revenue. The market in the region is expected to register significant growth over the forecast period due to the availability of developed medical infrastructure and treatment facilities in the region. Europe also contributes a moderate share and registered a healthy growth rate in the global ischemic optic neuropathy treatment market. The APEJ region has become a lucrative market for ischemic optic neuropathy treatment and is anticipated to register a significant share over the forecast period, due to the increase in research and development activities along with the growth in medical tourism in the region. Latin America and MEA are in the nascent stage in the global ischemic optic neuropathy treatment market and are expected to register moderate growth over the forecast period.

Some of the market players operating in the ischemic optic neuropathy treatment market include

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Read more:
The Ischemic Optic Neuropathy Treatment Market to remain unfazed by the Global Recession - Khabar South Asia

A new research study has been presented by dataintelo offering a comprehensive analysis on the Global Lebers Hereditary Optic Neuropathy Drug Market where user can benefit from the complete market research report with all the required useful information about this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments.

The Lebers Hereditary Optic Neuropathy Drug Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

Get a Free Sample Copy of the Lebers Hereditary Optic Neuropathy Drug Market Report with Latest Industry Trends @ https://dataintelo.com/request-sample/?reportId=127623

Major Players Covered in this Report are: Alkeus Pharmaceuticals, Inc.Biovista Inc.GenSight Biologics S.A.Ixchel Pharma, LLCKhondrion BVSpark Therapeutics, Inc.Stealth BioTherapeutics Inc.

Global Lebers Hereditary Optic Neuropathy Drug Market SegmentationThis market has been divided into Types, Applications, and Regions. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and value for the period between 2020 and 2026. This analysis can help you expand your business by targeting qualified niche markets. Market share data is available on the global and regional level. Regions covered in the report are North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Research analysts understand the competitive strengths and provide competitive analysis for each competitor separately.

By Types:ElamipretideGS-011IXC-201KH-176Others

By Applications:HospitalClinicOthers

To get Incredible Discounts on this Premium Report, Click Here @ https://dataintelo.com/ask-for-discount/?reportId=127623

Global Lebers Hereditary Optic Neuropathy Drug Market Regions and Countries Level AnalysisRegional analysis is a highly comprehensive part of this report. This segmentation sheds light on the sales of the Lebers Hereditary Optic Neuropathy Drug on regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the US, Canada, Mexico, Germany, France, the UK, Russia, Italy, China, Japan, South Korea, India, Australia, Brazil, and Saudi Arabia. The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Lebers Hereditary Optic Neuropathy Drug sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted. This study provides Lebers Hereditary Optic Neuropathy Drug sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Make an Inquiry of this Report @ https://dataintelo.com/enquiry-before-buying/?reportId=127623

Why Choose Us:

Table of Contents1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Market Overview5. Global Market Analysis and Forecast, by Types6. Global Market Analysis and Forecast, by Applications7. Global Market Analysis and Forecast, by Regions8. North America Market Analysis and Forecast9. Latin America Market Analysis and Forecast10. Europe Market Analysis and Forecast11. Asia Pacific Market Analysis and Forecast12. Middle East & Africa Market Analysis and Forecast13. Competition Landscape

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Read the rest here:
Leber's Hereditary Optic Neuropathy Drug Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - The Market Feed

For Evie Junior, living with sickle cell disease has been like running a marathon.

"But it's a marathon where as you keep going, the trail gets rockier and then you lose your shoes," the 27-year-old said. "It gets harder as you get older. Things start to fail and all you can think about is how much worse it's going to get down the road."

In sickle cell disease, a genetic mutation causes the blood-forming stem cells -- which give rise to all blood and immune cells -- to produce hard, sickle-shaped red blood cells. These misshapen cells die early, leaving an insufficient number of red blood cells to carry oxygen throughout the body. Because of their sickle shape, these cells also get stuck in blood vessels, blocking blood flow and resulting in excruciating bouts of pain that come on with no warning and can leave patients hospitalized for days.

The disease affects 100,000 people in the United States and millions around the world, the majority of whom are of African or Hispanic descent. It can ultimately lead to strokes, organ damage and early death.

As a child growing up in the Bronx, New York, Junior had to have his gall bladder and spleen removed due to complications from the disease, but he refused to let his condition limit him. He played football, basketball and baseball during the day, even though on some nights he experienced pain crises so severe he couldn't walk.

"It was just really routine if I had a sickle cell crisis," he said. "Going to the emergency room, staying in the hospital, coming out in a few days and then getting back to normal life."

'I want to create a better future'

When he was 24 and living in Portland, Oregon, Junior began working as an emergency medical technician. He adopted the same mentality -- trying to treat his pain episodes the best he could, and hoping they would resolve overnight so he could get back to work. Around that time, though, the crises became harder to manage. He developed pericarditis, an inflammation in the layers of tissue around his heart, and needed six weeks to recover.

"The big worry with sickle cell disease is that you're going to die young from some type of complications or damage to your organs," he said. "In the last couple of years, I've been seeing that slowly happen to me and I can only suspect that it's going to keep getting worse. I want to create a better future for myself."

In July 2019, in pursuit of that future, Junior enrolled in a clinical trial for an experimental stem cell gene therapy for sickle cell disease. The study is led by UCLA Broad Stem Cell Research Center physician-scientists Dr. Donald Kohn and Dr. Gary Schiller and funded by the California Institute for Regenerative Medicine.

The therapy, developed by Kohn over the past 10 years, is intended to correct the mutation in patients' blood-forming stem cells to allow them to produce healthy red blood cells. Kohn has already applied the same concept to successfully treat several immune system deficiencies, including a cure for a form of severe combined immune deficiency, also known as bubble baby disease.

But sickle cell disease has proven more difficult to treat with gene therapy than those other conditions. Junior volunteered for the trial knowing there was a chance the therapy wouldn't cure him.

"Even if it doesn't work for me, I'm hoping that it can be a cure later down the road for millions of people," he said.

In July 2020, Junior received an infusion of his own blood-forming stem cells that had been genetically modified to overcome the mutation that causes his disease.

"The goal of this treatment is to give him a future, let him plan for college, family or whatever he wants without worrying about getting hospitalized because of another pain crisis," said Kohn, a distinguished professor of microbiology, immunology and molecular genetics, pediatrics, and molecular and medical pharmacology at the David Geffen School of Medicine at UCLA.

Reason for optimism

Three months after his treatment, blood tests indicated that 70% of Junior's blood stem cells had the new corrected gene. Kohn and Schiller estimate that even a 20% correction would be enough to prevent future sickle cell complications. Junior said he hasn't had a pain crisis since undergoing the treatment and he has more energy and feels out of breath less often.

"I noticed a big difference in my cardiovascular endurance in general -- even going for a light jog with my dogs, I could feel it," he said.

Junior and his doctors are cautiously optimistic about the results.

"It's too early to declare victory, but it's looking quite promising at this point," Kohn said. "Once we're at six months to a year, if it looks like it does now, I'll feel very comfortable that he's likely to have a permanent benefit."

After a lifetime of dealing with the unwelcome surprises of the disease, Junior is even more cautious than his doctors. But as the weeks pass, he's slowly allowing a glimmer of hope that he could soon be someone who used to have sickle cell disease. For him, that hope feels like "a burst of happiness" that's followed by thoughts of all the things he could do with a healthy future: pursue his dream of becoming a firefighter, get married and start a family.

"I want to be present in my kids' lives, so I've always said I'm not going to have kids unless I can get this cured," he said. "But if this works, it means I could start a family one day."

Read more from the original source:
Gene therapy gives man with sickle cell disease the chance for a better future - Science Codex

This article was originally published here

J Vasc Interv Radiol. 2020 Nov 25:S1051-0443(20)30769-7. doi: 10.1016/j.jvir.2020.09.003. Online ahead of print.

ABSTRACT

PURPOSE: To evaluate safety and efficacy of angiogenesis induced by intraarterial autologous bone marrow-derived stem cell (BMSC) injection in patients with severe peripheral arterial disease (PAD).

MATERIALS AND METHODS: Eighty-one patients with severe PAD (77 men), including 56 with critical limb ischemia (CLI) and 25 with severe claudication, were randomized to receive sham injection (group A) or intraarterial BMSC injection at the site of occlusion (group B). Primary endpoints included improvement in ankle-brachial index (ABI) of > 0.1 and transcutaneous pressure of oxygen (TcPO2) of > 15% at mid- and lower foot at 6 mo. Secondary endpoints included relief from rest pain, > 30% reduction in ulcer size, and reduction in major amputation in patients with CLI and > 50% improvement in pain-free walking distance in patients with severe claudication.

RESULTS: Technical success was achieved in all patients, without complications. At 6 mo, group B showed more improvements in ABI of > 0.1 (35 of 41 [85.37%] vs 13 of 40 [32.50%]; P < .0001) and TcPO2 of > 15% at the midfoot (35 of 41 [85.37%] vs 17 of 40 [42.50%]; P = .0001] and lower foot (37 of 41 [90.24%] vs 19 of 40 [47.50%]; P < .0001). No patients with CLI underwent major amputation in group B, compared with 4 in group A (P = .0390). No significant difference was observed in relief from rest pain or > 30% reduction in ulcer size among patients with CLI or in > 50% improvement in pain-free walking distance among patients with severe claudication.

CONCLUSIONS: Intraarterial delivery of autologous BMSCs is safe and effective in the management of severe PAD.

PMID:33248918 | DOI:10.1016/j.jvir.2020.09.003

Read more here:
Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous...

(TNS) - Scientists at Bay Area universities, laboratories, biotechnology companies and drug manufacturers are fashioning drug concoctions out of blood plasma, chimpanzee viruses and cells taken from bone marrow in the race to rid the world of COVID-19.

The microbial treasure hunt is not just to find a cure which may not be possible but to control the debilitating health problems caused by the coronavirus.

Major progress has been made this year. The antiviral drug remdesivir, produced in Foster City, has improved recovery times, and the steroid dexamethasone has cut the number of deaths in severely ill patients.

What follows is a list of some of the most promising medications and vaccines with ties to the Bay Area:

Antibodies

and Immunity

Mesenchymal stem cells / UCSF and UC Davis Medical Center:

UCSF Dr. Michael Matthay is leading a study of whether a kind of stem cell found in bone marrow can help critically ill patients with severe respiratory failure, known as ARDS. Matthay hopes the stem cells can help reduce the inflammation associated with some of ARDS' most dire respiratory symptoms, and help patients' lungs recover.

In all, 120 patients are being enrolled at UCSF Medical Center, Zuckerberg San Francisco General Hospital, the UC Davis Medical Center in Sacramento and hospitals in Oregon and Texas. He said the trial, which includes a small number of ARDS patients who don't have COVID-19, should have results by summer or fall 2021. So far, 28 patients are enrolled in San Francisco.

Lambda-interferon / Stanford University:

Lambda-interferon is a manufactured version of a naturally occurring protein that had been used to treat hepatitis, and researchers hoped it would help patients in the early stages of COVID-19.

Stanford researchers completed their trial of lambda-interferon and found that it did not boost the immune system response to coronavirus infections.

"That trial did not find any difference in outcomes between the treatment and placebo," said Yvonne Maldonado, chief of pediatric infectious diseases at Lucile Packard Children's Hospital at Stanford, where 120 patients were enrolled in the trial. "It didn't work."

Antiviral drugs

Remdesivir / Gilead Sciences ( Foster City):

Remdesivir, once conceived as a potential treatment for Ebola, was approved by the Food and Drug Administration in October for use on hospitalized COVID-19 patients.

Trademarked under the name Veklury, the drug interferes with the process through which the virus replicates itself. It was one of the drugs given to President Trump and has been used regularly in hospitals under what is known as an emergency use authorization.

It was approved after three clinical trials showed hospitalized coronavirus patients who received remdesivir recovered five days faster on average than those who received a placebo. Patients who required oxygen recovered seven days faster, according to the studies.

Gilead now plans to conduct clinical trials to see how remdesivir works on pediatric patients, from newborns to teenagers, with moderate to severe COVID-19 symptoms. Remdesivir is also being studied with steroids and other drugs to see if it works better as part of a medicinal cocktail. An inhalable form of the drug is also being developed.

Favipiravir / Fujifilm Toyama Chemical ( Stanford University):

This antiviral drug, developed in 2014 by a subsidiary of the Japanese film company to treat influenza, is undergoing numerous clinical studies worldwide, including a trial involving 180 patients at Stanford University.

Stanford epidemiologists are testing favipiravir to see if it prevents the coronavirus from replicating in human cells, halts the shedding of the virus and reduces the severity of infection. Unlike remdesivir, it can be administered orally, so it can be used to treat patients early in the disease, before hospitalization is necessary.

The Stanford study has so far enrolled about 90 patients, who are given the drug within 72 hours of when they were first diagnosed with COVID-19. Half of them get a placebo. People can enroll by emailing treatcovid@stanford.edu.

Monoclonal antibodies

REGN-COV2 / Regeneron Pharmaceuticals / Stanford School of Medicine:

The REGN-COV2 cocktail is the same one Trump received, and Stanford is one of dozens of locations nationwide where clinical trials are being held. Two separate trials are under way at Stanford one for hospitalized patients, the other for outpatients. A third trial is about to begin for people who aren't sick but are in contact with carriers of the virus.

Regeneron halted testing on severely ill patients requiring high-flow oxygen or mechanical ventilation after the independent Data and Safety Monitoring Board determined that the drug was unlikely to help them.

The drug is a combination of two monoclonal antibodies lab-made clones of the antibodies produced naturally in people who have recovered from COVID-19. The antibodies bind to the virus' spike protein and block the virus' ability to enter cells.

Dr. Aruna Subramanian, professor of infectious diseases at Stanford and lead investigator for the inpatient trial, said the 21 hospitalized patients in the study receive a high dose like Trump, a lower dose or a placebo. Subramanian plans to expand the inpatient trial to 45 patients. The outpatient study has enrolled a little more than 40 of the 60 patients researchers intend to sign up.

"There's enough promising evidence that it helps people early in the infection," Subramanian said. "What we don't know is whether it helps people who are pretty sick but not critically ill."

Bamlanivimab / Eli Lilly / Stanford and UCSF:

Stanford and UCSF are testing the Eli Lilly monoclonal antibodies on outpatients after the pharmaceutical company halted trials on hospitalized COVID-19 patients because of adverse results.

Dr. Andra Blomkalns, chair of emergency medicine at Stanford and the lead in the Eli Lilly outpatient trial, said she is now enrolling older people with comorbidities like heart disease, chronic lung disease, a history of strokes and severe obesity shortly after they test positive.

The hypothesis is that the bamlanivimab monotherapy, which is very similar to the Regeneron monoclonals, might work best early in the infection. Although about 400 patients have been enrolled in the Lilly phase 3 trials nationwide, to date fewer than 10 have been enrolled at Stanford and UCSF.

Matthay, who headed up the Lilly monoclonal study with LY-CoV555 at UCSF, said the cancellation of this inpatient trial was disappointing, but "just because this one did not work, doesn't mean another one won't work for hospitalized patients."

Blomkalns said the testing criteria has been changing. She expects the outpatient trial to open soon to adolescents ages 12 and up to determine whether the drug can be used as a preventive.

Designer monoclonal antibodies / Vir Biotechnology, San Francisco:

Scientists at Vir are studying several types of monoclonal antibodies, including a type engineered to activate T cells, which can search out and destroy cells infected with the coronavirus. A study published in the journal Nature in October found that monoclonals, modified to bind with certain receptors, stimulated T cells and improved the human immune response.

"By observing and learning from our body's powerful natural defenses, we have discovered how to maximize the capacity of antibodies through the amplification of key characteristics that may enable more effective treatments for viral diseases," said Herbert Virgin, the chief scientific officer at Vir and co-author of the study.

A similarly modified monoclonal antibody, leronlimab, is being studied in coronavirus clinical trials by its Washington state drugmaker, CytoDyn, which has developed drugs to treat HIV. The company's chief medical officer is in San Francisco, and the company that does laboratory tests of leronlimab is in San Carlos.

Anti-inflammatory drugs

Colchicine / UCSF ( San Francisco and New York):

The anti-inflammatory drug commonly used to treat gout flare-ups is being studied by scientists at UCSF and New York University. The drug short-circuits inflammation by decreasing the body's production of certain proteins, and researchers hope that it will reduce lung complications and prevent deaths from COVID-19.

Preliminary results from a clinical trial found that "Colchicine can be effective in reducing systemic symptoms of COVID-19 by inhibiting inflammatory biomarkers."

Selinexor / Kaiser Permanente:

Kaiser hospitals in San Francisco, Oakland and Sacramento are studying selinexor, an anticancer drug that blocks a key protein in the cellular machinery for DNA processing. Preliminary findings during the trials indicated that low doses of selinexor helped hospitalized patients with severe COVID-19. The drug has both antiviral and anti-inflammatory properties, and it's administered orally, according to Kaiser's Dr. Jacek Skarbinski.

Vaccines

VXA-COV2-1 / Vaxart, South San Francisco:

The biotechnology company Vaxart is testing VXA-COV2-1, the only potential vaccine in pill form. It uses the genetic code of the coronavirus to trigger a defensive response in mucous membranes. The hope is that the newly fortified membranes will prevent the virus from entering the body.

"It's the only vaccine (candidate) that activates the first line of defense, which is the mucosa," said Andrei Floroiu, Vaxart's chief executive. He said intravenous vaccines kill the virus after it is inside the body, but this one stops it beforehand.

View original post here:
Coronavirus Updates: The Latest Treatments and Vaccines - GovTech

Graft Versus Host Disease (GVHD) Epidemiology

According to the National Cancer Institute (NCI), Graft versus host disease (GVHD) is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD occurs when particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.

GVHDhas two types Acute GVHDand Chronic GvHD. Acute GvHD is also known as fulminant GVHD and occurs usually in the initial 2-3 months after transplantation. Chronic GVHD occurs around 3-4 months after the transplantation has happened, and has more diverse complications. This type affects the liver, stomach, vagina, joints, lungs, gut, mouth and glands secreting mucus or saliva.

Get FREE sample copy at:https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-epidemiology-forecast

DelveInsights Graft Versus Host Disease (GVHD) Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Graft Versus Host Disease (GVHD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.The DelveInsight Graft Versus Host Disease (GVHD) epidemiology report gives a thorough understanding of the Graft Versus Host Disease (GVHD) disease symptoms and causes, along with the risk factors, diagnosis, pathophysiology associated with the disease, and. It also provides treatment algorithms and treatment guidelines for Graft Versus Host Disease (GVHD) in the US, Europe, and Japan. The report covers the detailed information of the Graft Versus Host Disease (GVHD) epidemiology scenario in seven major countries (US, EU5, and Japan).

Key Highlights Of The Report

As per a study by Elgaz S. et al., (2019), GVHDoccurs in 3050% of recipients and 14% of all patients suffer severe GVHDgrades 34. Chronic GVHDaffects 3070% of patients receiving allo-SCT.

As per a study by Jacobsohn and Vogelsang (n.d.) titled Acute graft versus host disease, in the United States, approximately 5,500 patients/year can develop acute GVHD and in 2003, the incidence of grade II-IV acute GVHD was roughly 3550%.

As per Orphanet, about 35%-50% of hematopoietic stem cell transplant (HSCT) recipients will develop acute Graft versus host disease (GVHD). And about 50% of patients with acute GVHD will eventually have manifestations of chronic GVHD.

Graft Versus Host Disease (GVHD) Epidemiology

Scope of the Report

Key Benefit of Graft Versus Host Disease (GVHD) Epidemiology Report

The Graft Versus Host Disease (GVHD) Epidemiology report will allow the user to

Get FREE sample copy at:https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-epidemiology-forecast

Table of Contents

*The table of contents is not exhaustive; will be provided in the final report

Related ReportsGraft versus host disease (GVHD)- Market Insight, Epidemiology and Market Forecast -2030DelveInsight s Graft versus host disease (GVHD) Market Insights, Epidemiology and Market Forecast 2030 report provides a detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

Graft versus host disease (GVHD) Pipeline Insights, 2020Graft versus host disease (GVHD) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Graft versus host disease (GVHD) market.

About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact usShruti Thakur[emailprotected]+91-9650213330https://www.delveinsight.com/LinkedIn | Facebook | TwitterGraft Versus Host Disease (GVHD) Epidemiology Report:https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-epidemiology-forecast

Here is the original post:
Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 - The Market Feed

Ottawa: There are more than 300,000 Canadians living with type 1 diabetes (T1D), an autoimmune disease with no known cause or cure, resulting in the dysfunction, damage or loss of pancreatic beta cells that produce insulin in our bodies. People with T1D must treat themselves with insulin several times per day to keep their blood glucose levels normal, and despite their best efforts, they often experience serious, and even life-threatening, complications.

To mark the end of Diabetes Awareness Month, Sonia Sidhu, Member of Parliament for Brampton South, on behalf of the Honourable Patty Hajdu, Minister of Health, announced an investment of $6 million through the CIHR-JDRF Partnership to Defeat Diabetes for two Canadian research teams to accelerate the development of stem cell-based therapies for the treatment of T1D.

Stem cells show great promise as a source of insulin-producing cells that could be transplanted to provide a new source of insulin, to replace dysfunctional, damaged or lost pancreatic beta cells. Canada has a remarkable legacy in leading discoveries in this area. Stem cells were discovered in Toronto in 1961, and in 2000, a team in Edmonton were the first to pioneer transplantation of pancreatic islets (the part of the pancreas that contains insulin-producing cells). These achievements represent important steps toward a treatment that will allow people with T1D to live healthy lives without daily insulin injections.

The research teams are led by Dr. Maria Cristina Nostro at the University Health Network and the University of Toronto and Dr. Francis Lynn at the BC Childrens Hospital Research Institute and the University of British Columbia. The teams will build on Canadas demonstrated research excellence and leadership in clinical islet transplantation, stem cell biology, diabetes, immunology and genetic engineering to accelerate stem cell-based therapies for T1D. They will work in collaboration with other Canadian researchers to tackle some of the biggest scientific challenges that impede our progress in this area and move us closer to a future where people with T1D will no longer rely on insulin therapy.

This funding was provided by the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes (CIHR-INMD), and JDRF Canada, through the CIHR-JDRF Partnership to Defeat Diabetes established in 2017. Each partner will invest $3 million over five years. This investment is part of a large research initiative, 100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes, funded by CIHR and partners. This initiative commemorates the 100th anniversary of the discovery of insulin to be marked in 2021a discovery that changed the lives of millions of Canadians and people around the world and won researchers Sir Frederick Banting and John Macleod the Nobel Prize in Physiology or Medicine.

See the original post:
Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - India Education Diary

Thursday evening's Our Health event gives local residents a chance to get answers to their questions regarding the disease

Getting answers about a debilitating medical condition can sometimes be a challenge.

Thats why Thursday's Our Health session will explore the toll arthritis exerts on area residents, who might be having trouble these days getting out of a chair or walking up the stairs at home.

It's serious, said Dr. Olivia Cheng, an orthopaedic surgeon at Georgian Bay General Hospital and Collingwood General and Marine Hospital.

One in five Canadians live every day with arthritis and there is no cure. Arthritis is a collection of conditions affecting joints and other tissues. It causes pain, restricts mobility and diminishes quality of life.

Entitled Living your Best Life with Arthritis, the live, virtual event goes Thursday at 7:30 p.m.Moderated by retired physician Keith Rose, Cheng and other panelists will discuss how residents can manage their symptoms and improve their quality of life through therapeutic exercise, physical activity and joint-replacement surgery.

According to the Canadian Arthritis Society, arthritis affects about 6 million Canadians. There are many types of arthritis, including non-inflammatory osteoarthritis or inflammatory such as rheumatoid arthritis.

Osteoarthritis affects one in six Canadians. It is a chronic disease which causes pain, stiffness, swelling and decreased movement in the hips, knees, fingers, toes or spine resulting from the bodys failed attempt to repair damaged joint tissue.

When we look at the impact of arthritis, we need to take into consideration other musculoskeletal disorders affecting the joints, ligaments, tendons, bones, etc., Cheng said. All of these can cause pain and functional limitations.

Arthritis is often written off as just arthritis, and a natural part of aging, however, the mortality, morbidity burden of arthritis and the economic cost of arthritis has been underestimated. As a result, people often live with arthritis for years before receiving appropriate help.

Cheng said its important to learn about the symptoms of arthritis and to seek appropriate help.

Early diagnosis and treatment of the illness can prevent or delay progression of the disease, she said. Also, managing the symptoms of arthritis can help you live a better life. The natural history of arthritis is that this disease will flare up intermittently with an overall progression over time.

According to Cheng, risk factors for arthritis that you can control include being overweight, previous injury to the joint and smoking with factors beyond ones control ranging from age, gender since its more common in women and genetics since inflammatory arthritis often runs in the family.

Once you are diagnosed with arthritis, then you can address the factors that are within your control, she said. These include strengthening exercises to help protect and unload your joint.

Keeping your weight healthy will help decrease the mechanical load on your joint and decrease the inflammatory factors in your body. Environmental factors such as eating food that minimizes inflammationand stopsmoking are also important.

For inflammatory arthritis such as rheumatoid arthritis, there are many advances in medications that can help control the disease progression.

Cheng said shes often asked about the wait list for total joint-replacement surgeries.

There is an increase in the prevalence of arthritis in Canada, the static trend in rates of joint-replacement procedures suggests that the system may be operating at capacity, she said. In our region, patients with arthritis are referred by their family doctors to a central intake clinic where they are assessed by an advanced-practice physiotherapist.

Patients who are candidates for surgery are then referred to either their preferred or next available surgeon. The limiting factors on the ability for us to perform joint-replacement surgery include the number of joints we are allocated by the health ministry, operating room availabilityand hospital capacity.

Thursdays event will be broadcast on Rogers TV channel 53 (Midland, Tay and Penetanguishene only). For those with smart phones, tablets or computers with a Wi-Fi connection, you can view online. Questions can be submitted to mccjared@mcc.com.

Originally posted here:
Help to alleviate the nagging, debilitating pain of arthritis - OrilliaMatters

In early November 2020, at the age of only 33, former British national champion and Omloop Het Nieuwslad winner Ian Stannard announced he would retire from professional cycling, having developed rheumatoid arthritis...but it doesn't have to mean the end of your time in the saddle.

> Health Q&A: Ischial bursitis more than just a saddle sore

So, what is rheumatoid arthritis, and how can it affect cyclists?In this Q+A, consultant rheumatologist at University Hospitals of Morecambe Bay NHS Trust and honorary senior lecturer at Manchester University Dr Marwan Bukhari explains why a diagnosis of rheumatoid arthritis doesnt have to stop you riding, and why cycling might actually help to preventdeveloping it in the first place...

road.cc: First of all, what is rheumatoid arthritis?

Marwan Bukhari: Rheumatoid arthritis is an auto-immune condition where your immune system decides to activate itself and starts attacking different parts of your body. It usually starts in the joints but it can affect most of the organs in your body, including the eyes, the lungs and the skin. So while it often begins in the joints, it can become far more widespread.

What causes it?

We dont actually know what causes it but its believed that there is a genetic component to it. We think that if you are exposed to an unspecified infection and you have the corresponding genetics, your immune system will activate itself and start by attacking the joints.

Ian Stannard'srheumatoid arthritisinitially presentedin his wrists, but can it present itself elsewhere?

Rheumatoid arthritis most commonly starts off in the hands and feet, then it can affect the knees, elbows and shoulders. Those are the normal joints where it starts, although it can present at any joint in your body - and there are quite a lot of joints in your body!

How would cyclists first spot that they might have an issue?

One of the things that will happen first is that you will start to feel very stiff first thing in the morning, and that will last for more than half an hour after getting up. You will then start to get specific pain and stiffness. For example, a cyclist might have problems grabbing the handlebar, or problems pedalling, with the area underneath the pad of their feet feeling particularly tender. The knees can also get a lot of fluid in them and feel quite tight.

Cyclists are always suffering from a bit of pain or stiffness is there a specific sign that it might be more than just normal activity strain or general fatigue?

Yes, if the pain is very specifically in the joints and if you discover that your motion is significantly restricted. For example, if it is in the hand, just grabbing the brake lever will be painful. You will get fatigue as well and you can get flu-like symptoms - because your immune system is active, its almost as if youre fighting an infection.

What should somebody do if they do think they have a potential problem with rheumatoid arthritis?

The most important thing is to understand that the time between symptom onset and starting treatment is crucial for the prognosis. In the old days, people used to think that anybody with rheumatoid arthritis would end up in a wheelchair or have deformities but that is not the case. If you can have treatment within four months of symptom onset that requires recognising whats happening, seeing your GP, having tests and being referred to a specialist then you can get the disease into remission. But that can only be done if we get the disease under control early enough. Then, to get rheumatoid arthritis into remission requires taking fairly high doses of immune-suppressing treatments. If youre on a fair amount of them, that could make you more susceptible to other problems such as infections, which is obviously a particular consideration in the current climate with so much focus on Covid-19.

How is a diagnosis of rheumatoid arthritis made?

There is a combination of things that are needed to provide a diagnosis. The first is clinical symptoms. Then we use two blood tests: one measures levels of rheumatoid factors, which are proteins that the immune system produces when it attacks healthy tissue; the other is known as anti-cyclic citrullinated peptide (anti-CCP), which are antibodies also produced by the immune system. Then that might be combined with some imaging - either x-rays or ultrasound imaging of the joints.

We tend to think of arthritis as an old persons condition, but Ian Stannard is only 33 so at what age can it develop?

Even children can develop inflammatory arthritis that looks exactly like rheumatoid, so it can happen from birth really. The most common ages are people in their 30s or 40s. It affects women more than men, but were now also seeing a form that appears in peoples 70s and that equally affects men and women. So all ages can be affected, and it affects around 1% of the population in the UK - there are more than 600,000 patients with rheumatoid arthritis in the UK.

Is there anything that makes cyclists more likely to develop rheumatoid arthritis? Or is there anything about cycling that aggravates it?

No, actually the evidence is that if you build the muscles around your joints and you use then a lot more, you can actually get better circulation and that helps to take away some of the accumulated toxins that your joints are producing. Your body is producing proteins that are telling your joints to get inflamed. But when you exercise youre actually taking the toxins away. So exercise is always very good.

What other steps can be taken to treat it?

There are lots of trials looking at diet modification using herbal remedies including turmeric and things such as that. There is some weak evidence that they will help your system because some foodstuffs do have naturally occurring anti-inflammatory properties. But usually the treatment is fairly heavy immune suppression with a possible amount of steroids as well. For professional athletes, these arent anabolic steroids but they might cross-react, so it could be quite tricky for high-level athletes to use them.

Finally then, although its not a diagnosis anybody would want, the outlook for people with rheumatoid arthritis doesnt have to be bleak?

Absolutely. As long as we catch it early enough and begin treatment, it is possible to get it under control.

For more information about rheumatoid arthritis, visit Versus Arthritis,or the National Rheumatoid Arthritis Society website,or call the NRAS helpline onHelpline number 0800 298 7650

See the original post here:
Rheumatoid arthritis and cycling: how to keep the inflammation at bay - road.cc

Woman's Doctor: Knowing the symptoms of psoriatic arthritis

Updated: 9:21 AM EST Nov 28, 2020

Hide TranscriptShow Transcript

LACEE: IN THIS MORNING'S WOMAN'S DOCTOR, KNOWING THE SYMPTOMS OF PSORIATIC ARTHRITIS, IT'S A DOUBLE WHAMMY OF AUTOIMMUNE DISORDERS. NOT ONLY DO PSORIATIC ARTHRITIS SYMPTOMS MIMIC THOSE OF PSORIASIS, LIKE PATCHES OF RED, SCALY SKIN, BUT THEY CAN ALSO CAUSE THE PAINFUL, SWOLLEN JOINTS THAT ARE COMMON WITH RHEUMATOID ARTHRITIS. THE SYMPTOMS CAN CHANGE FROM DAY TO DAY AND PERSON TO PERSON, MAKING PSORIATIC ARTHRITIS A PARTICULARLY TRICKY DISEASE TO DIAGNOSE AND MANAGE. MERCY MEDICAL CENTER DR. SADE YA KHAN SAYS THAT SYMPTOMS LEFT UNTREATED CAN LEAD TO PERMANENT JOINT DAMAGE. >> SYMPTOMS OF IT CAN BE INVOLVEMENT OF DIFFERENT AREAS OF THE SKELETON. IT COULD BE IN JOINT INVOLVEMENT, INCLUDING FINGERS AND FEET, WHICH WILL BE CONSIDERED SMALL JOINTS. IT COULD INVOLVE LARGER JOINTS, INCLUDING HIPS AND SHOULDERS. AND SOMETIMES, IT CAN ALSO AFFECT SPINE. LACEE: JOINING US THIS MORNING FROM MERCY MEDICAL CENTER, DR. JOSEPH CIO TOLA. THANK YOU FOR JOINING US. >> GOOD MORNING. LACEE: THIS SEEMS LIKE A PAINFUL CONDITION. TELL ME ABOUT THE BEGINNING SYMPTOMS OF PSORIATIC ARTHRITIS. >> IT'S SIMILAR TO REGULAR ARTHRITIS. JUST INFLAMED AND SWOLLEN, VERY SORE JOINTS. THEY GET A LOT OF FLUID BUILT UP ON THEM SOMETIMES. WE MANAGE THEM WITH CORTISONE INJECTIONS AND RELIEVING THE INFLAMMATION. LACEE: IS THIS SOMETHING THAT AFFECTS A CERTAIN GROUP MORE THAN OTHER? YOUNG OR OLD, MEN OR WOMEN? >> NO. NOT PARTICULARLY. IT CAN BE YOUNGER BECAUSE PSORIASIS CAN AFFECT YOUNGER PEOPLE. IT CAN AFFECT JOINTS AS WELL. LACEE: AT WHAT POINT IS IT TIME TO TALK TO A DOCTOR. IT CAN BE CONFUSED WITH PSORIASIS AT FIRST OR ARTHRITIS. >> WHEN SOMEBODY HAS PSORIASIS AND THEIR JOINTS BEGIN TO HURT, I THINK THAT'S THE TIME WHERE THEY NEED TO REALLY GET AGGRESSIVE WITH TREATING IT. LACEE: IN TERMS OF TREATMENT, WHERE DOES TREATMENT START FOR IT? >> IT STARTS WITH MANAGING THE INFLAMMATION. SO THEY WOULD SEE EITHER THEIR DERMATOLOGIST OR THEIR REGULAR PHYSICIAN TO GET ON ANTIINFLAMMATORY REGIMEN. AND THEN WHEN IT COMES TO THE POINT WHERE THEY'RE READY FOR AN ORTHOPEDIC SURGEON, WE BEGIN MANAGING IT BY CONTROLLING THE INFLAMMATION AT THE JOINT LEVEL WITH INJECTIONS. LACEE: WHAT KIND OF POSSIBLE SURGERY COULD THIS LEAD TO? >> IT LEADS TO JOINT REPLACEMENT. IT'S VERY SIMILAR TO RHEUMATOID ARTHRITIS. WHEN THE CARTILAGE IS ERODED ENOUGH AND THE JOINT CAN'T RECOVER, WE REPLACE IT. LACEE: IS IT SOMETHING THAT YOU CAN CURE? >> NO, IT'S JUST MANAGEMENT. IT'S MANAGEMENT OF THE INFLAMMATION. LACEE: WHAT CAN YOU DO TO PREVENT IT IN THE FIRST PLACE? >> I MEAN, I THINK YOU WANT TO BE AS HEALTHY AS POSSIBLE. ANTIINFLAMMATORY DIET AND DOING THE BEST YOU CAN TO CONTROL SUGAR AND INFLAMMATORY PRODUCTS IN YOUR LIFE STYLE. BUT THAT'S REALLY ABOUT IT. LACEE: GOT TO STAY HEALTHY. >> IT'S NOT SOMETHING WE CAN CURE. LACEE: THIS TIME OF YEAR IS HARD BECAUSE THERE'S A LOT OF SUGAR AND THAT STUFF IN FRONT OF US. THANKS FOR TAKING TIME OUT OF YOUR MORNING TO JOIN US. APPRECIATE

Woman's Doctor: Knowing the symptoms of psoriatic arthritis

Updated: 9:21 AM EST Nov 28, 2020

Psoriatic arthritis is a double-whammy of autoimmune disorders. Not only do psoriatic arthritis symptoms mimic those of psoriasis -- like patches of red, scaly skin -- but they can also cause the painful, swollen joints that are common with rheumatoid arthritis. Mercy Medical Center's Dr. Joseph Ciotola explains.

Psoriatic arthritis is a double-whammy of autoimmune disorders. Not only do psoriatic arthritis symptoms mimic those of psoriasis -- like patches of red, scaly skin -- but they can also cause the painful, swollen joints that are common with rheumatoid arthritis. Mercy Medical Center's Dr. Joseph Ciotola explains.

See the rest here:
Woman's Doctor: Knowing the symptoms of psoriatic arthritis - WBAL TV Baltimore

A novel outpatient procedure offers lasting pain relief for patients suffering from moderate to severe arthritis in their hip and shoulder joints.

According to a study presented at the annual meeting of the Radiological Society of North America, researchers said the procedure could help reduce reliance on addictive opiates.

People with moderate to severe pain related to osteoarthritis face limited treatment options. Common approaches like injections of anesthetic and corticosteroids into the affected joints grow less effective as the arthritis progresses and worsens.

Usually, over time patients become less responsive to these injections, said Felix M. Gonzalez, M.D., from the Radiology Department at Emory University School of Medicine in Atlanta, Georgia. The first anesthetic-corticosteroid injection may provide six months of pain relief, the second may last three months, and the third may last only a month. Gradually, the degree of pain relief becomes nonsignificant.

Without pain relief, patients face the possibility of joint replacement surgery. Many patients are ineligible for surgery because of health reasons, whereas many others choose not to go through such a major operation.

CHECK OUT: First Ever Study Shows Chair Yoga is Effective Arthritic Treatment

For those patients, the only other viable option may be opiate painkillers, which carry the risk of addiction.

Dr. Gonzalez and colleagues have been studying the application of a novel interventional radiology treatment known as cooled radiofrequency ablation (c-RFA) to achieve pain relief in the setting of advanced degenerative arthritis. The procedure involves the placement of needles where the main sensory nerves exist around the shoulder and hip joints. The nerves are then treated with a low-grade current known as radiofrequency that stuns them, slowing the transmission of pain to the brain.

For the new study, 23 people with osteoarthritis underwent treatment, including 12 with shoulder pain and 11 with hip pain that had become unresponsive to anti-inflammatory pain control and intra-articular lidocaine-steroid injections.

Treatment was performed two to three weeks after the patients received diagnostic anesthetic nerve blocks. The patients then completed surveys to measure their function, range of motion and degree of pain before and at three months after the ablation procedures.

There were no procedure-related complications, and both the hip and shoulder pain groups reported statistically significant decrease in the degree of pain with corresponding increase in dynamic function after the treatment.

In our study, the results were very impressive and promising, Dr. Gonzalez said. The patients with shoulder pain had a decrease in pain of 85%, and an increase in function of approximately 74%. In patients with hip pain, there was a 70% reduction in pain, and a gain in function of approximately 66%.

RELATED:Molecule Combo Actually Reverses Arthritis in Human Cartilage and Rats, Says Exciting New Study

The procedure offers a new alternative for patients who are facing the prospect of surgery. In addition, it can decrease the risk of opiate addiction.

This procedure is a last resort for patients who are unable to be physically active and may develop a narcotic addiction, Dr. Gonzalez said. Until recently, there was no other alternative for the treatment of patients at the end of the arthritis pathway who do not qualify for surgery or are unwilling to undergo a surgical procedure.

At last years RSNA annual meeting, Dr. Gonzalez presented similarly encouraging results from a study of a similar procedure for the treatment of knee arthritis. Together, the knee, shoulder and hip articulations account for approximately 95% of all arthritis cases.

The procedure could have numerous applications outside of treating arthritic pain, Dr. Gonzalez explained. Potential uses include treating pain related to diseases like cancer and sickle cell anemia-related pain syndrome, for example.

MORE:Hydrolyzed Collagen Supplements Are Good for Health: Benefitting Hair, Skin, Joints, and Muscles

Were just scratching the surface here, Dr. Gonzalez said. We would like to explore efficacy of the treatment on patients in other settings like trauma, amputations, and especially in cancer patients with metastatic disease.

Source:Radiological Society of North America

Share The Good News With Your Friends By Sharing It To Social Media

The rest is here:
Sufferers Living With Severe Arthritis Could be Given Lasting Pain Relief Thanks to a New Technique - Good News Network

Contributors: MLH, EAH, DN, BG, KHP, TU, GG, M, RvV designed the study and wrote the protocol. RvV, DN, MSH, EAH, Niels Steen Krogh, DG, SK, MLH developed the CRFs. MLH, EAH, AR, DN, MN, BG, JL, KHP, TU, GG, M, MSH, SK, JL, AKHE, KLG, MK, FF, RT, TL, GC, EBa, OH, DV, TSI, TH, MKAL, EBr, TE, AS, MR, RO, PL, LU, SAJ, DJS, TBL, GB, RvV contributed to the data collection and data cleaning. SK and Niels Steen Krogh did data management. JT and ICO conducted the statistical analyses. ICO and SK made the figures. MLH wrote the manuscript with input from all authors. All authors had access to the raw dataset and vouch for the veracity of the results. All authors read and approved the final version of the manuscript including the decision to submit the paper. MLH and RvV are guarantors of the overall content, accept full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: Funding was obtained through public sources: Academy of Finland (grant No 258536), Finska Lkaresllskapet, grant from the South-Eastern Health Region, Norway, HUCH Institutional grant, Finland (grant No 1159005), Icelandic Society for Rheumatology, interregional grant from all health regions in Norway, NordForsk (grant No 70945), Regionernes Medicinpulje, Denmark (grant No 14/217), Stockholm County Council, Sweden (grant No 20100490), Swedish Medical Research Council (grant No C0634901, D0342301, 2015-00891_5), Swedish Rheumatism Association, The Research Fund of University Hospital, Reykjavik, Iceland (A2015017). UCB supported the work in the context of an investigator initiated study where UCB provided certolizumab pegol at no cost. UCB had no role in study design, collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit for publication. Bristol-Myers Squibb (BMS) provided abatacept at no cost. In addition, the Karolinska Institute received several unrestricted grants from BMS; these were subsequently transferred to the principal investigators of Denmark, Finland, and the Netherlands to help defray various trial related costs at the local level. BMS had no role in study design, collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit for publication. The final manuscript was provided for courtesy review to UCB and BMS in line with Good Publication Practice (GPP3). We confirm the independence of researchers from funders and that all authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility of the integrity of the data and the accuracy of the data analysis.

Competing interests: All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: support from Academy of Finland, Finska Lkaresllskapet, South-Eastern Health Region (Norway), HUCH (Finland), Icelandic Society for Rheumatology, all health regions in Norway, NordForsk, Regionernes Medicinpulje (Denmark), Stockholm County Council (Sweden), Swedish Medical Research Council, Swedish Rheumatism Association, The Research Fund of University Hospital (Reykjavik, Iceland) for the submitted work; MLH reports grants from Nordforsk, from Danske Regioner during the conduct of the study; grants from Bristol-Myers Squibb, grants from AbbVie, grants from Roche, grants from Novartis, grants and personal fees from Merck, grants and personal fees from Biogen, grants and personal fees from Pfizer, personal fees from Eli Lilly, personal fees from Orion Pharma, personal fees from CellTrion, personal fees from Samsung Bioepsi, personal fees from Janssen Biologics BV, personal fees from MSD, outside the submitted work; she chairs the steering committee of the Danish Rheumatology Quality Registry (DANBIO), which receives public funding from the hospital owners and funding from pharamaceutical companies; EAH reports grants from NORDFORSK, grants from the Norwegian Regional Health Authorities, grants from the South-Eastern Norway Regional Health Authority, during the conduct of the study; personal fees from Pfizer, personal fees from AbbVie, personal fees from Celgene, personal fees from Novartis, personal fees from Janssen, personal fees from Gilead, personal fees from Eli-Lilly, personal fees from UCB, outside the submitted work; AR reports grants from the Swedish Research Council, financial support from AstraZeneca, outside the submitted work; DN reports grants from UCB, grants from BMS, during the conduct of the study; grants from AbbVie, grants from Celgene, grants from MSD, grants from Novartis, grants from Pfizer outside the submitted work; MN reports grants from BMS, during the conduct of the study; grants from Abbvie, grants from BMS, personal fees from Celltrion, grants from MSD, grants from Pfizer, personal fees from Eli Lilly, grants from Amgen, outside the submitted work; BG reports personal fees from Novartis, outside the submitted work; TU reports a grant from NORDFORSK during the conduct of the study; personal fees from Grnenthal, personal fees from Lilly, personal fees from Novartis, personal fees from Pfizer, outside the submitted work; M reports grants, personal fees and non-financial support from AbbVie, grants, personal fees and non-financial support from BMS, personal fees from Boehringer-Ingelheim, personal fees from Eli Lilly, personal fees and non-financial support from Janssen, grants, personal fees and non-financial support from Merck, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from UCB, grants and personal fees from Celgene, personal fees from Sanofi, personal fees from Regeneron, grants, personal fees and non-financial support from Novartis, personal fees from Orion, personal fees from Hospira, outside the submitted work; MSH reports grants from the South-Eastern Norway Regional Health Authority, during the conduct of the study; personal fees from Lilly, outside the submitted work; SK reports receiving grants from AbbVie, MSD and Novartis outside the submitted work; AKHE reports receiving personal fees from AbbVie, personal fees from Pfizer, outside the submitted work; KLG reports grants from BMS, outside the submitted work; RT reports grants from Finnish Rheumatology Research Fund, during the conduct of the study; OH reports non-financial support from Pfizer, personal fees from Abbvie, personal fees from Novartis, during the conduct of the study; TSI reports non-financial support from DiaGraphIT, personal fees from Abbvie, personal fees from BMS, personal fees from Celgene, personal fees from Medac, personal fees from Merck, personal fees from Novartis, personal fees from Orion Pharma, personal fees from Pfizer, personal fees from Roche, personal fees from Sandoz, personal fees from UCB, personal fees from Bohringer Ingelheim, outside the submitted work; LU reports personal fees from Abbvie, Eli Lilly and Novartis (speaker fees), outside the submitted work; DJS reports grants from KLINBEFORSK, during the conduct of the study; TBL reports personal fees from UCB, outside the submitted work; GB reports personal fees from BMS, outside the submitted work; ABA reports personal fees from Abbvie, personal fees from Eli Lilly, personal fees from Novartis, personal fees from Pfizer, outside the submitted work; AB reports grants from BMS, during the conduct of the study; CT reports grants and personal fees from Bristol Myers-Squibb, personal fees from Roche, personal fees from Abbvie, personal fees from Pfizer, outside the submitted work; HR reports personal fees from MSD, personal fees from Roche, personal fees from Abbvie, personal fees from Celgene, outside the submitted work; JR reports grants from BMS, during the conduct of the study; JW reports fees from Celgene, fees from Eli Lilly, fees from Novartis, outside the submitted work; KM reports personal fees from Abbvie, personal fees from Celgene, personal fees from Medac, personal fees from BMS, outside the submitted work; OKS reports grants from the Research Committee of the Kuopio University Hospital Catchment Area for the State Research Funding, during the conduct of the study; non-financial support from Pfizer, non-financial support from Novartis, non-financial support from MSD, personal fees from Boeringer Ingelheim, outside the submitted work; PP reports personal fees from Novartis Finland Oy, outside the submitted work; R reports personal fees from Bristol-Meyer Squibb, personal fees and non-financial support from AbbVie, personal fees from Gilead, personal fees from Janssen, personal fees from Eli-Lilly, personal fees from Novartis, outside the submitted work; SNC reports personal fees from Bristol Myers Squibb, personal fees from General Electric, outside the submitted work; SE reports personal fees from Novartis, outside the submitted work; TO reports personal fees from Eli Lilly, consultancy fee from Merck Sharp and Dohme, outside the submitted work; reports grants from BMS, during the conduct of the study; grants from Roche, grants from Mylan, other from Abbvie, outside the submitted work; VR reports grants from BMS, during the conduct of the study; grants from Roche, grants from Mylan, other from Abbvie, outside the submitted work; RvV reports grants from BMS, during the conduct of the study; grants from BMS, GSK, Lilly, UCB, grants from Pfizer, Roche, personal fees from AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Servier, UCB, outside the submitted work; no other relationships or activities that could appear to have influenced the submitted work.

See the rest here:
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised,...

Known for his rock 'n' roll antics and attitude, Liam Gallagher may need to take better care of his health as he enters middle age. It was only last year when the star revealed he has arthritis in his hip.

Named as William John Paul Gallagher at birth, the 48-year-old has matured in the spotlight.

Twice divorced, and the father of four children, Liam did a candid interview with Q Magazine in June 2019.

It was there he stated he suffers from arthritis in his hip - a painful inflammatory condition.

Dad to Molly (22), Lennon (21), Gene (19) and Gemma (seven), Liam is still keen to maintain his rock 'n' roll image.

Due to his arthritis, he has developed calf pain he's been seeking treatment for.

Speaking about his acupuncture treatment, he said: "This geezer is mega, he doesnt f**k about.

"He gets the needles and whacks them in. He sorts it but it keeps coming back. Acupuncture is alright, at least its needles."

READ MORE:Coronavirus vaccine roll out priority: List outlines who in britain will get jab first

Another charity, Versus Arthritis, said: "Its common to have aches and pains in your muscles and joints from time to time.

"This may especially be true if you take part in unusual or strenuous physical activities."

This can make it difficult to identify the warning signs of arthritis, but the charity makes it crystal clear on how you can spot the disease early.

"If you have swelling or stiffness that you cant explain and that doesn't go away in a few days, or if it becomes painful to touch your joints, you should see a doctor," it advised.

If you're diagnosed with arthritis, you may be offered medical treatments.

In addition to medication, Versus Arthritis encourage sufferers to exercise.

"Exercise can make symptoms such as pain and swelling better," it certified.

Low-impact exercises are typically recommended, such as cycling, brisk walking, yoga, T'ai Chi and pilates.

Be aware that "some discomfort and pain" is expected when you exercise, but it "should calm down a few minutes after you finish".

However, "it's important to not overdo it" added the charity. "The key is to start off gently and to gradually increase the amount you do."

Physical activity also helps you to maintain a healthy weight (or achieve one), which can put less pressure on the joints.

This in turn can help relieve the painful effects of arthritis.

See the original post here:
Liam Gallagher health: Rockstar has arthritis in his hip- what is this condition? - Express

A recent grant to UAB researchers from a national organization will yield insight into telehealth and potentially increase patient access to rheumatic care.

Jeffrey Curtis, M.D.The need for virtual health care options has significantly increased because of the COVID-19 pandemic. UAB researchers and collaborators have received a two-year, $400,000 grant from the American College of Rheumatologys Rheumatology Research Foundation to support telehealth-delivered health care.

Jeffrey Curtis, M.D., professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham, will use this grant to support the project Telehealth-delivered Healthcare to Improve Care THRIVE in community-practice rheumatology. The projects collaborators include Cedars-Sinai Medical Center, CreakyJoints, a digital arthritis community for patients and caregivers worldwide, and its ArthritisPower research registry. The THRIVE projects primary investigator, Swamy Venuturupalli, M.D., is the recipient of this years ACRs Norman B. Gaylis, M.D., Clinical Research Award, and is slated to begin in January of 2021.

This grant is an exciting opportunity to identify and build best-in-class approaches to telehealth and to test specific strategies to assess patients with inflammatory arthritis, particularly rheumatoid arthritis, Curtis said. Clinical trials and routine patient care have been severely hampered by COVID-19-related perturbations in care delivery. We will scope and validate methods for disease activity assessment using telehealth-related technology, coupled with remote patient monitoring capabilities, including digitally captured, patient-reported outcome data.

The THRIVE project seeks to define, solidify and incorporate the best practices in telehealth rheumatology, disseminating these tools to community rheumatologists everywhere through a variety of channels.

The ultimate goal of this project is to increase patient access to care, expand the impact of rheumatology especially for those marginalized or most at risk by the COVID-19 pandemic and enable and improve the value of care provided by rheumatology providers in community settings through telehealth.

We are excited about the partnership between academia, community practitioners and arthritis patient communities, in what we expect to be a model paradigm for collaborative, practice-based research now and into the future, Curtis said.

Read the rest here:
Rheumatology Research Foundation grant allows for advancement in telehealth - The Mix

This report on Psoriatic Arthritis Treatment market, published by DataIntelo, is an in-depth analysis that studies crucial aspects of the market, which will assist clients to make right decision about their business investment plans and strategies. The market report entails a detailed information regarding the key segments and sub-segmentations including the product types, applications, and regions by examining the emerging market size, performance, and scope of each segment of the Psoriatic Arthritis Treatment.

Keeping 2019 as the base year, the report evaluates the extensive data available of the Global Psoriatic Arthritis Treatment Market for the historical period, 2015-2018 and assess the market trend for the forecast period from 2020 to 2026. With an aim to supply a robust assessment of the market, the report offers vital insights on industry growth opportunities and development, drivers and restrains for the Psoriatic Arthritis Treatment market with focusing on consumers behavior and industrial trend for the prior years as well as the base year.

Request a sample before buying this report @ https://dataintelo.com/request-sample/?reportId=118149

One key aspect of the report is that it provides an extensive study on the impact of COVID-19 pandemic on the global market and explains how it would affect the future business operations of the industry. In short, DataIntelos report provides an in-depth analysis of the overall market structure of Psoriatic Arthritis Treatment and assesses the possible changes in the current as well as future competitive scenarios of the Psoriatic Arthritis Treatment market. Reflecting the pandemic effects, the report also includes information regarding the changing market scenario, competition landscape of the companies, and the flow of the global supply and consumption.

Besides describing the market positions of various major key players for the Psoriatic Arthritis Treatment market, the report makes a concrete assessment on the key strategies and plans formulated by them over the recent years. In addition to this, the report provides information about recent developments such as product launch, entering merger and acquisition, partnership and collaboration, and expansion of the production plants by some key players.

This report includes the estimation of market size for value (USD) and volume (K MT), with applying top-down and bottom-up approaches to estimate and validate the overall scope of the Psoriatic Arthritis Treatment market. The report is prepared with a group of graphical representations, tables, and figures which displays a clear picture of the developments of the products and its market performance over the last few years. With this precise report, it can be easily understood the growth potential, revenue growth, product range, and pricing factors related to the Psoriatic Arthritis Treatment market.

Request a sample before buying this report @ https://dataintelo.com/request-sample/?reportId=118149

The published report consists of a robust research methodology by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the companies related to the Psoriatic Arthritis Treatment market. It also includes comments and suggestions from the experts in the market especially the representatives from government and public organizations as well as international NGOs. The report prepared by DataIntelo is known for its data accuracy and precise style, which relies on genuine information and data source. Moreover, customized report can be available as per the clients wishes or specific needs.

Key companies that are covered in this report:

Eli LillyRocheMerckNovartisAbbvieAmgenBristol Myers SquibbCelgene CorporationJanssenValeant Pharmaceuticals

*Note: Additional companies can be included on request

The report covers a detailed performance of some of the key players and analysis of major players in the industry, segments, application, and regions. Moreover, the report also considers the governments policies in different regions which illustrates the key opportunities as well as challenges of the market in each region.

By Application:

HospitalsClinicsAmbulatory Surgery CentersDiagnostic Laboratories

By Type:

KitsReagentsInstruments

As per the report by DataIntelo, the Psoriatic Arthritis Treatment market is projected to reach a value of USDXX by the end of 2026 and grow at a CAGR of XX% through the forecast period (2020-2026). The report describes the current market trend of the Psoriatic Arthritis Treatment in regions, covering North America, Latin America, Europe, Asia Pacific, and Middle East & Africa by focusing the market performance by the key countries in the respective regions. According to the need of the clients, this report can be customized and available in a separate report for the specific region.

You can also go for a yearly subscription of all the updates on Psoriatic Arthritis Treatment market.

You can buy the complete report @ https://dataintelo.com/checkout/?reportId=118149

Why you should buy this report?

This report provides a complete guideline for the clients to arrive an informed business decisions since it entails a comprehensive information, which will help the clients to understand better of the current & future market situation.

Apart from that, the report also answers some of the key questions given below:

If you have any questions on this report, please reach out to us @ https://dataintelo.com/enquiry-before-buying/?reportId=118149

About DataIntelo

DataIntelo is a globally leading market research company that has an excellent group of long-year experienced team in the field of business research. We keep our priority to fulfil the needs of our customers by offering authentic and inclusive reports for the global market-related domains. With a genuine effort from a dedicated team of business experts, DataIntelo has been in the service for years by providing innovative business ideas and strategies for the current global market for various industries and set its benchmark in the market research industry.

We have a large support of database from various leading organizations and business executives across the globe. With this leverage, we excel at customized report as per the clients requirement and updating market research report on the daily basis with quality information.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Continue reading here:
Psoriatic Arthritis Treatment Market To 2026: Growth Analysis By Manufacturers, Regions, Types And Applications - The Market Feed

BOULDER, Colo. The CBDMEDIC brand, now part of the Charlottes Web, Inc. family of hemp CBD wellness products, and an official Impact Sponsor for the Arthritis Foundation, announces its matching funds campaign for Giving Tuesday. On Dec. 2nd CBDMEDIC will match individual donations made to the Arthritis Foundation up to a total sum of $50,000.

To those on Giving Tuesday who donate $50 or more to the Arthritis Foundation, CBDMEDIC will ship a free thank you gift of its Arthritis Aches and Pain Relief Cream, a retail value of $39.99 The Arthritis Foundation continues to pursue a cure for Americas number one cause of disability, and provides advocacy, community connections, and educational resources to those battling arthritis. The Giving Tuesday donations and CBDMEDIC matching funds donation will support scientific research, legislation and life-improvement programs led by the Arthritis Foundation. CBDMEDIC is the only hemp CBD brand to be approved and serve as an Arthritis Foundation Impact Sponsor.

According to GivingTuesday.org, last year more than 13% of the U.S. population participated in Giving Tuesday raising $511M online to support thousands of nonprofits. To participate in the CBDMEDICs Giving Tuesday Matching Funds Campaign donors may link here beginning at midnight Dec. 1 through midnight Dec. 2, 2020.

The Arthritis Foundation is leading the charge to find solutions that make a life-changing impact for people with arthritis. Partnering with CBDMEDIC helps bring greater awareness around the challenges of living with arthritis, which includes managing chronic pain, said Rick Willis, Senior Vice President, Community Engagement. We appreciate their commitment to providing the arthritis community with topical alternatives for temporary pain relief.

Especially in these uncertain times, due to the pandemic, it is vitally important that businesses and their brands step up and support nonprofits like the Arthritis Foundation this Giving Tuesday, said Deanie Elsner, CEO of Charlottes Web, Inc. Our CBDMEDIC brand is offering $50,000 in matching funds so that the Arthritis Foundations work in scientific research and advocacy can continue to benefit the millions of Americans suffering from arthritis. This is also a part of our Charlottes Web mission to help people heal through compassion and science. We encourage everyone who is able to do so to give this Giving Tuesday to the Arthritis Foundation.

According to the Center for Disease Control, 22.7% of adults in US have doctor-diagnosed arthritis (or one in four adults). And, About 43.5% (or 23.7 million) of people with arthritis (54.4 million) have limitations in their daily activities due to their arthritis.

CBDMEDIC is now part of the Charlottes Web family of hemp-derived CBD brands sold online <https://www.charlottesweb.com/cbd-medic>, as well as in more than 4,500 retail stores, according to Nielsen data (9/5/2020). CBDMEDIC top-selling products for those suffering from the symptoms of arthritis, as well as pain and inflammation, include its Back & Neck Pain Relief Ointment, Arthritis Aches & Pain Relief Ointment, Arthritis Aches & Pains Hand Cream, Active Sport Pain Relief Stick, Muscle & Joint Pain Relief Spray and Muscle & Joint Pain Relief Ointment.

Find out more about CBDMEDIC topical pain relief products.

About the Arthritis Foundation:The Arthritis Foundation is the Champion of Yes. Leading the fight for the arthritis community, the Foundation helps conquer everyday battles through life-changing information and resources, access to optimal care, advancements in science and community connections. The Arthritis Foundations goal is to chart a winning course, guiding families in developing personalized plans for living a full life and making each day another stride toward a cure. Visit arthritis.org to learn more.

About CBDMEDICLaunched in 2019 and now sold in more than 4,500 retail stores, the CBDMEDIC brand offers a line of 15 THC-free and hemp-derived CBD topical pain relief products that provide revolutionary pain relief. CBDMEDIC products combine naturally derived pain-relieving pharmaceutical ingredients along with natural emollients (skin softening ingredients) and essential oils, and THC-free hemp extract to create unique formulations for fast and effective relief. CBDMEDIC formulations combine advanced science with organic and natural ingredients to provide safe relief. CBDMEDIC products are offered across the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.

About Charlottes Web Holdings, Inc.Charlottes Web Holdings, Inc., a Certified B Corporation headquartered in Boulder, Colo., is the market leader in the production and distribution of innovative hemp-derived cannabidiol (CBD) wellness products under a family of brands which includes Charlottes Web, CBD Medic, CBD Clinic, and Harmony Hemp. The Companys premium quality products start with proprietary hemp genetics that are 100-percent American farm grown and manufactured into whole-plant hemp extracts containing a full spectrum of naturally occurring phytocannabinoids including CBD, CBC, CBG, terpenes, flavonoids and other beneficial hemp compounds. Charlottes Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, stress, inflammation recovery), CBD capsules, CBD topical creams and lotions, as well as CBD pet products for dogs. Charlottes Web is the number one CBD brand in the USA and distributed through more than 22,000 retail locations, select distributors and online through the Companys website at http://www.CharlottesWeb.com.

Charlottes Web was founded by the Stanley Brothers with a mission to unleash the healing powers of botanicals through compassion and science, benefiting the planet and all who live upon it. Charlottes Web is a socially and environmentally conscious company and is committed to using business as a force for good and a catalyst for innovation. The Company weighs sound business decisions with consideration for how its efforts affect employees, customers, the environment, and diverse communities. The rate the Company pays for agricultural products reflects a fair and sustainable rate driving higher quality yield, encouraging regenerative farming practices, and supporting U.S. farming communities. Management believes that its socially oriented and environmentally responsible actions have a positive impact on its customers, suppliers, employees and stakeholders. Charlottes Web donates a portion of its pre-tax earnings to charitable organizations.

Read the original here:
CBDMEDIC to Match $50000 in Funds for Arthritis Foundation on Giving - CBD Today